FDG-PET / MRI as a predictor of response to neoadjuvant chemotherapy in patients with epithelial ovarian primary peritoneal or fallopian tube cancer.
Brief description of study
If you have been diagnosed with ovarian, peritoneal or fallopian tube cancer, you may qualify for this study. The main goal of this trial is to determine the ability of FDG-PET combined with MRI as a predictor of neoadjuvant chemotherapy. This study will also collect the tumor molecular profiling for patients with ovarian, primary peritoneal, or fallopian tube cancers.
Clinical Study Identifier: s14-01714
ClinicalTrials.gov Identifier: NCTs14-01714
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
